Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, jeopardizes the health of patients with cancer by delaying treatment and creating unnecessary barriers, according to a recent position statement from the Community Oncology Alliance (COA).
Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, jeopardizes the health of patients with cancer by delaying treatment and creating unnecessary barriers, according to a recent position statement from the Community Oncology Alliance (COA).
Step therapy, or so-called “fail-first” policies, are common in chronic conditions such as for autoimmune disorders or diabetes, but for patients with cancer who may not have the luxury of time, it can create unnecessary delays or denials; COA said that, unlike some other conditions, with cancer “the wrong choice as initial therapy can be life-threatening.” In addition, there are few therapeutic and generic-to-brand substitutes in oncology treatments, COA said.
“Patients on fail-first step therapy are forced to receive potentially inferior or incorrect treatment options that their treating physicians considered and specifically did not prescribe,” COA said.
COA called insurers and pharmacy benefit managers (PBMs) “third-party middlemen” and said step therapy “forces patients and their physicians to try cheaper, often older, treatments before they are allowed access to state-of-the-art, newer therapies, which are often more expensive. This is despite the recommendation of the treating physician who believes the cheaper treatment would not work.”
Although plans include an appeal process in step therapy programs, they are insufficient, COA said, because step therapy stops patients from receiving evidence-based treatment and presents burdensome hurdles to patients and providers.
While step therapy is common in commercial insurance, it became part of HHS’ strategy to control costs this year when Medicare Advantage began allowing it as well. A bipartisan group of senators recently introduced a bill to curb the use of step therapy.
Instead of focusing on medical needs, the goal of step therapy is to zero in on financial interests to maximize profits and control costs, COA said. Some reports have cited step therapy as a way to increase uptake of biosimilars; earlier this year, COA released a position statement about biosimilars, saying it would work with stakeholders to support the acceptance of biosimilars as well as work to close knowledge gaps.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.